Alpha 2.0
Login Register
» Authors » Sharmila Pimple

Sharmila Pimple

Explore the profile of Sharmila Pimple including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 28
Citations 550
Followers 0
Related Specialties
Oncology
Gynecology & Obstetrics
Allergy & Immunology
Top 10 Co-Authors
Gauravi Mishra
Richard Muwonge
Rengaswamy Sankaranarayanan
Neerja Bhatla
Smita Joshi
Yogesh Verma
Partha Basu
Usha Rani Reddy Poli
Eric Zomawia
Sylla G Malvi
Published In
Lancet Oncol
Asian Pac J Cancer Prev
Vaccine
Papillomavirus Res
Gynecol Oncol Rep
Affiliations
Soon will be listed here.
Recent Articles
1.
Association between high-risk human papillomavirus and cervico-vaginal infections in tribal women screened for cervical precancers and cancers in Maharashtra, India: A cross-sectional study
Munne K, Birje S, Patil A, Akula A, Mayekar A, Bhekare G, et al.
Indian J Dermatol Venereol Leprol . 2025 Mar; :1-9. PMID: 40033917
Background The vaginal microenvironment is thought to impact infection and persistence of the human papillomavirus which is a necessity for cervical carcinogenesis. Tribal women are at risk for human papillomavirus...
2.
A prospective cohort study comparing efficacy of 1 dose of quadrivalent human papillomavirus vaccine to 2 and 3 doses at an average follow up of 12 years postvaccination
Malvi S, Esmy P, Muwonge R, Joshi S, Poli U, Lucas E, et al.
J Natl Cancer Inst Monogr . 2024 Nov; 2024(67):317-328. PMID: 39529521
Background: While recommending a human papillomavirus (HPV) single-dose vaccination schedule in 2022, the World Health Organization highlighted the need for long-term follow-up studies to monitor waning of protection. We report...
3.
Case studies on the progress of cervical cancer screening programs in Bhutan, India, and Türkiye
Burdier F, Bolio A, Abraham P, Pimple S, Franco E, Pempa P, et al.
Vaccine . 2024 Nov; 42 Suppl 2:S49-S53. PMID: 39521573
International stakeholders gathered in New Delhi, India, in December 2022 to share experiences on human papillomaviruses (HPV) prevention and control strategies. As part of a supplementary publication from the meeting...
4.
Impact of age at vaccination and cervical HPV infection status on binding and neutralizing antibody titers at 10 years after receiving single or higher doses of quadrivalent HPV vaccine
Bhatla N, Muwonge R, Malvi S, Joshi S, Poli U, Lucas E, et al.
Hum Vaccin Immunother . 2023 Dec; 19(3):2289242. PMID: 38078840
Long-term follow-up of a cohort of unmarried girls who received one, two, or three doses of quadrivalent HPV vaccine, between 10 and 18 years of age, in an Indian multi-centric...
5.
Surviving the Storm: The Impact of COVID-19 on Cervical Cancer Screening in Low- and Middle-Income Countries
Vahabi M, Shahil-Feroz A, Lofters A, Wong J, Prakash V, Pimple S, et al.
Healthcare (Basel) . 2023 Dec; 11(23). PMID: 38063647
According to the Center for Disease Control and Prevention's National Breast and Cervical Cancer Early Detection Program, the cervical cancer screening rate dropped by 84% soon after the declaration of...
6.
Immunogenicity and safety of a new quadrivalent HPV vaccine in girls and boys aged 9-14 years versus an established quadrivalent HPV vaccine in women aged 15-26 years in India: a randomised, active-controlled, multicentre, phase 2/3 trial
Sharma H, Parekh S, Pujari P, Shewale S, Desai S, Bhatla N, et al.
Lancet Oncol . 2023 Nov; 24(12):1321-1333. PMID: 37949086
Background: To meet global cervical cancer elimination efforts, a wider range of affordable and accessible vaccines against human papillomavirus (HPV) are needed. We aimed to evaluate the immunogenicity and safety...
7.
Novel educational training of para medical professionals in cervical cancer screening
Raj S, Kattepur A, Shylasree T, Mishra G, Patil A, Pimple S, et al.
Gynecol Oncol Rep . 2023 Jul; 48:101241. PMID: 37520786
Background: Cervical cancer is a public health problem in India due to weak national screening policy compounded by lack of resources including scarcity of trained personnel to carry out community-based...
8.
Health-Related Quality of Life (HRQoL) Using EQ-5D-5L: Value Set Derived for Indian Breast Cancer Cohort
Wadasadawala T, Mohanty S, Sen S, Khan P, Pimple S, Mane J, et al.
Asian Pac J Cancer Prev . 2023 Apr; 24(4):1199-1207. PMID: 37116141
Objective: The purpose of this study was to report quality of life of newly diagnosed breast cancer patients from India in a large cohort using the EQ-5D-5L instrument. Methods: The...
9.
Effectiveness of family-centred sexual health education and HPV self-sampling in promoting cervical cancer screening among hard-to-reach indian women in rural and tribal areas: a community-based pilot study
Vahabi M, Mishra G, Pimple S, Wong J, Khan M, Prakash V, et al.
BMC Public Health . 2023 Apr; 23(1):671. PMID: 37041530
Background: While cervical cancer deaths have declined steeply in high-income countries due to the widespread use of the Papanicolaou test (Pap test), the same trend has not emerged in low...
10.
Evaluation of immune response to single dose of quadrivalent HPV vaccine at 10-year post-vaccination
Joshi S, Anantharaman D, Muwonge R, Bhatla N, Panicker G, Butt J, et al.
Vaccine . 2022 Nov; 41(1):236-245. PMID: 36446654
Background: The recent World Health Organization recommendation supporting single-dose of HPV vaccine will significantly reduce programmatic cost, mitigate the supply shortage, and simplify logistics, thus allowing more low- and middle-income...